Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01504854 · ClinicalTrials.gov registry record · Phase 2
Resveratrol for Alzheimer's Disease
A Phase 2 study, sponsored by Alzheimer's Disease Cooperative Study (ADCS).
- Completed
- Registry status
- Phase 2
- Development phase
- 119
- Enrollment target
NCT01504854 is a Phase 2 study that has completed, run by Alzheimer's Disease Cooperative Study (ADCS). The registered enrollment target is 119 participants.
The verdict
NCT01504854, a Phase 2 study, has completed, sponsored by Alzheimer's Disease Cooperative Study (ADCS).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 119 participants
- Enrollment target
Study Summary
Resveratrol is derived from plants and is found in highest levels in red wine and the skin of red grapes. A recent study reported that monthly and weekly consumption of red wine is associated with a lower risk of dementia. There is compelling evidence that caloric restriction can improve overall health by activating a class of enzymes known as Sirtuins. Resveratrol is a substance found in some plants that directly activates sirtuins, mimicking the effects of caloric restriction and may affect regulatory pathways of diseases of aging, including Alzheimer's disease (AD). In this study, people with AD will be given either Resveratrol or placebo for 12 months to determine whether daily resveratrol therapy is beneficial in delaying or altering the deterioration of memory and daily functioning. Subjects age 50 and above with a diagnosis of probable AD may qualify for participation in this study. A small group of 15 participants will be asked to take part in a more detailed 24-hour Pharmacokinetic (PK) sub-study that will measure resveratrol levels over a 24 hour period.
Interventions
- DRUG Placebo
- DRUG Resveratrol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2012-05 |
| Est. Completion | 2014-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01504854
The ClinicalTrials.gov registry entry for NCT01504854 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alzheimer's Disease Cooperative Study (ADCS), which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01504854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01504854 about?
NCT01504854 is a clinical study titled "Resveratrol for Alzheimer's Disease". Resveratrol is derived from plants and is found in highest levels in red wine and the skin of red grapes. A recent study reported that monthly and weekly consumption of red wine is associated with a lower risk of dementia. There is compelling evidence that caloric restriction can improve overall hea...
What is the current status of trial NCT01504854?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 119 participants. The study started on 2012-05. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01504854?
The interventions under investigation include: Placebo (DRUG), Resveratrol (DRUG).
Who is sponsoring clinical trial NCT01504854?
This trial is sponsored by Alzheimer's Disease Cooperative Study (ADCS), which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.